Capsiate Composition for Inflammatory and Autoimmune Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases, angiogenesis-related diseases, and autoimmune diseases often come with severe side effects and limited efficacy, with a need for new substances that can effectively suppress inflammatory responses, angiogenesis, and immune responses without adverse reactions.
Innovation Solution
A pharmaceutical composition comprising capsiate or dihydrocapsiate, or their pharmaceutically acceptable salts, is developed to prevent and treat inflammatory diseases, angiogenesis-related diseases, and autoimmune diseases by inhibiting inflammatory mediators, angiogenesis factors, and immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antihistaminic agents, vitamin ointments, and adrenocorticotropic hormones are used to treat inflammatory diseases, then inflammatory symptoms are temporarily relieved, but severe side reactions occur and effects are not sustained
Solution Approach 1:
The patent changes the chemical parameter from conventional anti-inflammatory drugs (antihistaminic agents, adrenocorticotropic hormones) to capsiate, a natural compound with different chemical properties. Capsiate suppresses inflammatory mediators including prostaglandins, leukotrienes, and cytokines through a different mechanism of action, achieving anti-inflammatory effects without the severe side reactions of conventional drugs
Solution Approach 2:
The patent applies capsiate specifically to target inflammatory pathways and angiogenesis factors locally at the site of inflammation. The compound selectively inhibits COX-2, iNOS, and VEGF expression in inflamed tissues without affecting normal physiological functions systemically, thereby reducing side effects while maintaining therapeutic efficacy
2Reliability
If protease inhibitors, tyrosine kinase inhibitors, chemokines, interleukins and fragments of matrix proteins are developed as angiogenesis inhibitors, then angiogenesis-related diseases may be treated, but few treatments are available that can effectively suppress angiogenesis
Solution Approach 1:
The patent changes the approach from using multiple different classes of angiogenesis inhibitors (protease inhibitors, tyrosine kinase inhibitors, chemokines, interleukins) to a single natural compound, capsiate. This compound effectively suppresses angiogenesis by inhibiting VEGF, bFGF, and MMP expressions through its unique chemical structure and mechanism, simplifying the therapeutic approach while maintaining efficacy
3Reliability
If immunosuppressants are used to treat autoimmune diseases, then immune response is suppressed, but severe side effects and limited efficacy occur
Solution Approach 1:
The patent changes from conventional immunosuppressants to capsiate, which modulates immune response through a different mechanism. Capsiate suppresses the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and inhibits NF-κB activation, achieving immunomodulatory effects without the severe side effects of traditional immunosuppressants
Solution Approach 2:
The patent converts the harmful overactive immune response in autoimmune diseases into a beneficial controlled response. Capsiate selectively suppresses pathogenic immune mechanisms (excessive cytokine production, NF-κB activation) while preserving normal immune function, thereby treating autoimmune diseases without causing immunosuppression-related side effects
Data Source
AI summary
The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity.